WallStreetZenWallStreetZen

NASDAQ: APTO
Aptose Biosciences Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for APTO

Based on 3 analysts offering 12 month price targets for Aptose Biosciences Inc.
Min Forecast
$5.00+296.83%
Avg Forecast
$15.33+1,116.9%
Max Forecast
$23.00+1,725.4%

Should I buy or sell APTO stock?

Based on 3 analysts offering ratings for Aptose Biosciences Inc.
Strong Buy
Strong Buy
1 analysts 33.33%
Buy
2 analysts 66.67%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their APTO stock forecasts and price targets.

APTO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-03
lockedlocked$00.00+00.00%2024-03-27
lockedlocked$00.00+00.00%2023-11-10

1 of 1

Forecast return on equity

Is APTO forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.72%

Forecast return on assets

Is APTO forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

APTO revenue forecast

What is APTO's revenue in the next 1 years based on estimates from 1 analyst?
Avg 1 year Forecast
$12.2M

APTO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
APTO$1.26$15.33+1,116.90%Strong Buy
TCRT$1.24N/AN/A
RNXT$1.19$4.00+236.13%Strong Buy
BIOR$0.64$50.00+7,688.16%Buy
VINC$0.95N/AN/A
View Top Biotech Stocks

Aptose Biosciences Stock Forecast FAQ

Is Aptose Biosciences Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: APTO) stock is to Strong Buy APTO stock.

Out of 3 analysts, 1 (33.33%) are recommending APTO as a Strong Buy, 2 (66.67%) are recommending APTO as a Buy, 0 (0%) are recommending APTO as a Hold, 0 (0%) are recommending APTO as a Sell, and 0 (0%) are recommending APTO as a Strong Sell.

If you're new to stock investing, here's how to buy Aptose Biosciences stock.

What is APTO's revenue growth forecast for 2026-2026?

(NASDAQ: APTO) Aptose Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.32%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.27%.

Aptose Biosciences's revenue in 2024 is $0.

In 2026, APTO is forecast to generate $190,970,067 in revenue, with the lowest revenue forecast at $190,970,067 and the highest revenue forecast at $190,970,067.

What is APTO's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: APTO) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is APTO's Price Target?

According to 3 Wall Street analysts that have issued a 1 year APTO price target, the average APTO price target is $15.33, with the highest APTO stock price forecast at $23.00 and the lowest APTO stock price forecast at $5.00.

On average, Wall Street analysts predict that Aptose Biosciences's share price could reach $15.33 by Apr 3, 2025. The average Aptose Biosciences stock price prediction forecasts a potential upside of 1,116.9% from the current APTO share price of $1.26.

What is APTO's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: APTO) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.